Related references
Note: Only part of the references are listed.The Association Between Statin Use and Outcomes in Patients Initiating Androgen Deprivation Therapy
Robert J. Hamilton et al.
EUROPEAN UROLOGY (2021)
The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiotoxicity JACC: CardioOncology Primer
Lili Zhang et al.
JACC: CARDIOONCOLOGY (2021)
Cardioprotective strategies to prevent breast cancer therapy-induced cardiotoxicity
Allison Padegimas et al.
TRENDS IN CARDIOVASCULAR MEDICINE (2020)
Proteasome Inhibitor Drugs
Lloyd D. Fricker
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 60 (2020)
Heart failure and atrial tachyarrhythmia on abiraterone: A pharmacovigilance study
Marie Bretagne et al.
ARCHIVES OF CARDIOVASCULAR DISEASES (2020)
Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations
G. Curigliano et al.
ANNALS OF ONCOLOGY (2020)
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
Cora N. Sternberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
Neal D. Shore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib
Panagiotis Efentakis et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque
Zsofia D. Drobni et al.
CIRCULATION (2020)
CHIP phosphorylation by protein kinase G enhances protein quality control and attenuates cardiac ischemic injury
Mark J. Ranek et al.
NATURE COMMUNICATIONS (2020)
Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer The PRONOUNCE Trial Study Design
Chiara Melloni et al.
JACC: CARDIOONCOLOGY (2020)
Cardiac Disease in Childhood Cancer Survivors Risk Prediction, Prevention, and Surveillance: JACC CardioOncology State-of-the-Art Review
Jan M. Leerink et al.
JACC: CARDIOONCOLOGY (2020)
Cardiotoxicity Surveillance and Risk of Heart Failure During HER2 Targeted Therapy
Anthony F. Yu et al.
JACC: CARDIOONCOLOGY (2020)
Dual Angiotensin Receptor-Neprilysin Inhibition With Sacubitril/Valsartan Attenuates Systolic Dysfunction in Experimental Doxorubicin-Induced Cardiotoxicity
Nabil E. Boutagy et al.
JACC: CARDIOONCOLOGY (2020)
Machine Learning Identifies Clinical and Genetic Factors Associated With Anthracycline Cardiotoxicity in Pediatric Cancer Survivors
Marie-A Chaix et al.
JACC: CARDIOONCOLOGY (2020)
Cardiac adverse events of immune checkpoint inhibitors in oncology patients: A systematic review and meta-analysis
Nso Nso et al.
WORLD JOURNAL OF CARDIOLOGY (2020)
Immune Checkpoint Inhibitor Therapy Aggravates T Cell-Driven Plaque Inflammation in Atherosclerosis
Kikkie Poels et al.
JACC: CARDIOONCOLOGY (2020)
Genetics of Anthracycline Cardiomyopathy in Cancer Survivors JACC: CardioOncology State-of-the-Art Review
Smita Bhatia
JACC: CARDIOONCOLOGY (2020)
Clinical Development of BRAF plus MEK Inhibitor Combinations
Vivek Subbiah et al.
TRENDS IN CANCER (2020)
Cardiovascular Effects of CAR T Cell Therapy A Retrospective Study
Benedicte Lefebvre et al.
JACC: CARDIOONCOLOGY (2020)
Cardiac Adverse Events in EGFR-Mutated Non-Small Cell Lung Cancer Treated With Osimertinib
Kei Kunimasa et al.
JACC: CARDIOONCOLOGY (2020)
Human-Induced Pluripotent Stem Cell Model of Trastuzumab-Induced Cardiac Dysfunction in Patients With Breast Cancer
Tomoya Kitani et al.
CIRCULATION (2019)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Leveraging Signaling Pathways to Treat Heart Failure With Reduced Ejection Fraction Past, Present, and Future
Miguel Pinilla-Vera et al.
CIRCULATION RESEARCH (2019)
Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome
Chelsea Kotch et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2019)
Cardiovascular Morbidity in a Randomized Trial Comparing GnRH Agonist and GnRH Antagonist among Patients with Advanced Prostate Cancer and Preexisting Cardiovascular Disease
David Margel et al.
JOURNAL OF UROLOGY (2019)
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study
Kohei Shitara et al.
LANCET ONCOLOGY (2019)
Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma
Robert F. Cornell et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Mitochondrial oxidative stress plays a critical role in the cardiotoxicity of sunitinib Running title: Sunitinib and oxidative stress in hearts
Jamal Bouitbir et al.
TOXICOLOGY (2019)
Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin
Panagiotis Efentakis et al.
BLOOD (2019)
Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer
Funda Meric-Bernstam et al.
CLINICAL CANCER RESEARCH (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T)
Raza M. Alvi et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Renin-Angiotensin-Aldosterone System Modulates Blood Pressure Response During Vascular Endothelial Growth Factor Receptor Inhibition
Wendy J. Bottinor et al.
JACC: CARDIOONCOLOGY (2019)
Efficacy of Neurohormonal Therapies in Preventing Cardiotoxicity in Patients With Cancer Undergoing Chemotherapy
Muthiah Vaduganathan et al.
JACC: CARDIOONCOLOGY (2019)
Increase in Blood Pressure Associated With Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor
Sarah Waliany et al.
JACC: CARDIOONCOLOGY (2019)
Efficacy of Dexrazoxane in Preventing Anthracycline Cardiotoxicity in Breast Cancer
Ariane V. S. Macedo et al.
JACC: CARDIOONCOLOGY (2019)
Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity A Phase I Trial
Darryl P. Leong et al.
JACC: CARDIOONCOLOGY (2019)
Osimertinib-Induced Cardiotoxicity A Retrospective Review of the FDA Adverse Events Reporting System (FAERS)
Kartik Anand et al.
JACC: CARDIOONCOLOGY (2019)
Cardiovascular Adverse Events Associated With BRAF and MEK Inhibitors A Systematic Review and Meta-analysis
Raluca I. Mincu et al.
JAMA NETWORK OPEN (2019)
Mitochondrial ROS Drive Sudden Cardiac Death and Chronic Proteome Remodeling in Heart Failure
Swati Dey et al.
CIRCULATION RESEARCH (2018)
The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer
Roberto Iacovelli et al.
CLINICAL GENITOURINARY CANCER (2018)
Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer
Suresh S. Ramalingam et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
Syed S. Mahmood et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Metformin Use is Associated with Improved Survival for Patients with Advanced Prostate Cancer on Androgen Deprivation Therapy
Kyle A. Richards et al.
JOURNAL OF UROLOGY (2018)
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
Reinhard Dummer et al.
LANCET ONCOLOGY (2018)
Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis
Chintan Shah et al.
LEUKEMIA & LYMPHOMA (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
G. K. Abou-Alfa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The Role of Apelin in Cardiovascular Diseases, Obesity and Cancer
Marta B. Wysocka et al.
FRONTIERS IN PHYSIOLOGY (2018)
Carfilzomib-Associated Cardiovascular Adverse Events A Systematic Review and Meta-analysis
Adam J. Waxman et al.
JAMA ONCOLOGY (2018)
Irreversible proteasome inhibition with carfilzomib as first line therapy in patients with newly diagnosed multiple myeloma: Early in vivo cardiovascular effects
Mara Gavazzoni et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2018)
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors A Systematic Review and Meta-analysis
Daniel Y. Wang et al.
JAMA ONCOLOGY (2018)
Increased Afterload Augments Sunitinib-Induced Cardiotoxicity in an Engineered Cardiac Microtissue Model
Rachel Truitt et al.
JACC-BASIC TO TRANSLATIONAL SCIENCE (2018)
Rutin Attenuates Carfilzomib-Induced Cardiotoxicity Through Inhibition of NF-κB, Hypertrophic Gene Expression and Oxidative Stress
Faisal Imam et al.
CARDIOVASCULAR TOXICOLOGY (2017)
Molecular Mechanisms of the Cardiotoxicity of the Proteasomal-Targeted Drugs Bortezomib and Carfilzomib
Brian B. Hasinoff et al.
CARDIOVASCULAR TOXICOLOGY (2017)
Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity
Edith Pituskin et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
N. D. James et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
T. S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Gαi is required for carvedilol-induced β1 adrenergic receptor β-arrestin biased signaling
Jialu Wang et al.
NATURE COMMUNICATIONS (2017)
Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials
Raphael B. Moreira et al.
ONCOTARGET (2017)
Spasmogenic Effects of the Proteasome Inhibitor Carfilzomib on Coronary Resistance, Vascular Tone and Reactivity
Carol Chen-Scarabelli et al.
EBIOMEDICINE (2017)
A Novel Positron Emission Tomography (PET) Approach to Monitor Cardiac Metabolic Pathway Remodeling in Response to Sunitinib Malate
Alice C. O'Farrell et al.
PLOS ONE (2017)
Sex differences in vascular physiology and pathophysiology: estrogen and androgen signaling in health and disease
Austin C. Boese et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2017)
The antineoplastic drug, trastuzumab, dysregulates metabolism in iPSC-derived cardiomyocytes
Brian M. Necela et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2017)
'Real-life' experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors
Sophia Danhof et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2016)
Commentary on Huggins and Hodges: Studies on Prostatic Cancer
William G. Nelson
CANCER RESEARCH (2016)
Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 x 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol
Geeta Gulati et al.
EUROPEAN HEART JOURNAL (2016)
Use of beta-blockers, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and breast cancer survival: Systematic review and meta-analysis
Sara Raimondi et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Trastuzumab, but Not Pertuzumab, Dysregulates HER2 Signaling to Mediate Inhibition of Autophagy and Increase in Reactive Oxygen Species Production in Human Cardiomyocytes
Nishant Mohan et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
P. Moreau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Douglas B. dbj Johnson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Apremilast reversed carfilzomib-induced cardiotoxicity through inhibition of oxidative stress, NF-κB and MAPK signaling in rats
Faisal Imam et al.
TOXICOLOGY MECHANISMS AND METHODS (2016)
Apremilast reversed carfilzomib-induced cardiotoxicity through inhibition of oxidative stress, NF-κB and MAPK signaling in rats
Faisal Imam et al.
TOXICOLOGY MECHANISMS AND METHODS (2016)
Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer A Randomized Clinical Trial
Annelies H. Boekhout et al.
JAMA ONCOLOGY (2016)
Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805
Naomi B. Haas et al.
CLINICAL CANCER RESEARCH (2015)
Angiotensin System Inhibitors and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma
Rana R. McKay et al.
CLINICAL CANCER RESEARCH (2015)
Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors
Pooja Ghatalia et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)
Genetically induced moderate inhibition of 20S proteasomes in cardiomyocytes facilitates heart failure in mice during systolic overload
Mark J. Ranek et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2015)
Intracoronary Cytoprotective Gene Therapy A Study of VEGF-B167 in a Pre-Clinical Animal Model of Dilated Cardiomyopathy
Felix Woitek et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2015)
Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma
Tadeusz Robak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
A. Keith Stewart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study
Giorgio Gandaglia et al.
BJU INTERNATIONAL (2014)
Tumour co-expression of apelin and its receptor is the basis of an autocrine loop involved in the growth of colon adenocarcinomas
Francois-Xavier Picault et al.
EUROPEAN JOURNAL OF CANCER (2014)
Association Between Use of β-Blockers and Prostate Cancer-Specific Survival: A Cohort Study of 3561 Prostate Cancer Patients with High-Risk or Metastatic Disease
Helene Hartvedt Grytli et al.
EUROPEAN UROLOGY (2014)
Daily Aspirin Use and Prostate Cancer-Specific Mortality in a Large Cohort of Men with Nonmetastatic Prostate Cancer
Eric J. Jacobs et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy REPLY
Tomasz M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Incidence and Risk of Cardiotoxicity Associated with Bortezomib in the Treatment of Cancer: A Systematic Review and Meta-Analysis
Yi Xiao et al.
PLOS ONE (2014)
Cancer Therapy-Induced Cardiotoxicity: Basic Mechanisms and Potential Cardioprotective Therapies
Virginia Shalkey Hahn et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
T. M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone
Anna Pia et al.
CANCER TREATMENT REVIEWS (2013)
Impaired Assembly and Post-translational Regulation of 26S Proteasome in Human End-Stage Heart Failure
Sharlene M. Day et al.
CIRCULATION-HEART FAILURE (2013)
Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies
David Siegel et al.
HAEMATOLOGICA (2013)
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Testosterone Supplementation in Male Obese Zucker Rats Reduces Body Weight and Improves Insulin Sensitivity But Increases Blood Pressure
Deborah D. Davis et al.
HYPERTENSION (2012)
Treatment of bevacizumab-induced hypertension by amlodipine
Olivier Mir et al.
INVESTIGATIONAL NEW DRUGS (2012)
Cardiovascular and Systemic Microvascular Effects of Anti-Vascular Endothelial Growth Factor Therapy for Cancer
J. Todd Belcik et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Temporal Trends in Cause of Death Among Swedish and US Men with Prostate Cancer
Mara M. Epstein et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Statins Induce the Accumulation of Regulatory T Cells in Atherosclerotic Plaque
Xiao Meng et al.
MOLECULAR MEDICINE (2012)
Vemurafenib: the first drug approved for BRAF-mutant cancer
Gideon Bollag et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Risk of cardiac dysfunction with trastuzumab in breast cancer patients: A meta-analysis
Tao Chen et al.
CANCER TREATMENT REVIEWS (2011)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Dennis Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors.
Eric Raymond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Proteasome functional insufficiency activates the calcineurin-NFAT pathway in cardiomyocytes and promotes maladaptive remodelling of stressed mouse hearts
Mingxin Tang et al.
CARDIOVASCULAR RESEARCH (2010)
Cardiomyocyte PDGFR-β signaling is an essential component of the mouse cardiac response to load-induced stress
Vishnu Chintalgattu et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Mitogen-Activated Protein Kinase Signaling in the Heart: Angels Versus Demons in a Heart-Breaking Tale
Beth A. Rose et al.
PHYSIOLOGICAL REVIEWS (2010)
Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis
Xiaolei Zhu et al.
ACTA ONCOLOGICA (2009)
Tyrosine Kinase Inhibitors - A Review on Pharmacology, Metabolism and Side Effects
Joerg Thomas Hartmann et al.
CURRENT DRUG METABOLISM (2009)
Androgen Signaling in Myocytes Contributes to the Maintenance of Muscle Mass and Fiber Type Regulation But Not to Muscle Strength or Fatigue
Jill Ophoff et al.
ENDOCRINOLOGY (2009)
Blockade of the erbB2 Receptor Induces Cardiomyocyte Death through Mitochondrial and Reactive Oxygen Species-dependent Pathways
Leo I. Gordon et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice
Julie A. Lucas et al.
JOURNAL OF IMMUNOLOGY (2008)
Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis
Shenhong Wu et al.
LANCET ONCOLOGY (2008)
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
Tammy F. Chu et al.
LANCET (2007)
The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis
M. M. Moasser
ONCOGENE (2007)
Proatherogenic immune responses are regulated by the PD-1/PD-L pathway in mice
Israel Gotsman et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
b-arrestin-mediated β1-adrenergic receptor transactivation of the EGFR confers cardioprotection
Takahisa Noma et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Drug therapy: Trastuzumab - Mechanism of action and use in clinical practice
Clifford A. Hudis
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib: From rational design to clinical efficacy
Laura Q. M. Chow et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
Nancy L. Keating et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure
KS Chong et al.
EUROPEAN JOURNAL OF HEART FAILURE (2006)
Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome
M Groll et al.
STRUCTURE (2006)
Identification and regulation of Sprouty1, a negative inhibitor of the ERK cascade, in the human heart
RC Huebert et al.
PHYSIOLOGICAL GENOMICS (2004)
Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition
JF Ohren et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2004)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice
T Okazaki et al.
NATURE MEDICINE (2003)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
ErbB2 is essential in the prevention of dilated cardiomyopathy
SA Crone et al.
NATURE MEDICINE (2002)
Differential regulation of mitogen-activated protein kinases in the failing human heart in response to mechanical unloading
M Flesch et al.
CIRCULATION (2001)
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
MEK1/2-ERK1/2 mediates α1-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes
L Xiao et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2001)
The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice
OF Bueno et al.
EMBO JOURNAL (2000)
Share Paper
